Breast cancer is the leading cause of cancer in women in China. Preoperative chemotherapy for treatment of locally advanced breast cancer has become a standard therapy. Results from neoadjuvant trials have shown that pathological complete response (pCR) is an independent predictor of outcome. Paclitaxel was introduced into clinical practice in the early 1990s and has demonstrated good activity in the adjuvant and metastatic settings. Platinum complexes, like cisplatin and carboplatin, are active in a wide range of solid tumors. Paclitaxel combined with carboplatin has shown great activity in ovarian and nonsmall- cell lung cancer treatment. In addition, the overall response rate of paclitaxel plus carboplatin was between 53% and 62% in the first-line treatment of metastatic breast cancer. This study will evaluate the pCR rate of weekly paclitaxel plus carboplatin as preoperative treatment for breast cancer patients ...

In August 2009, during a major restructuring activity, BMS acquired the biotechnology firm Medarex as part of the companys String of Pearls strategy of alliances, partnerships and acquisitions.[28] In November, Bristol-Myers Squibb announced that it was splitting off Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson. According to Bristol-Myers Squibb, this move was expected to further sharpen the companys focus on biopharmaceuticals. In October 2010, the company acquired ZymoGenetics, securing an existing product as well as pipeline assets in hepatitis C, cancer and other therapeutic areas. Bristol-Myers Squibb agreed to pay around $2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead/Pharmasset to produce Hepatitis C drugs. The settlement will be finished in 2 months for its Inhibitexs shareholders acceptance of 126 percent premium price of its price over the previous 20 trading days ended on ...

Disclosure of Interest T. W. J. Huizinga Grant/research support from: EU & Dutch Arthritis Foundation, Consultant for: Abbott Laboratories, Biotest AG, Bristol-Myers Squibb, Crescendo Bioscience, Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche, sanofi-aventis, Schering-Plough, UCB, Inc., Eli Lilly, Meteor Board, Speakers bureau: Abbott Laboratories, Biotest AG, Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche, sanofi-aventis, Schering-Plough, S. E. Connolly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, A. Johnsen Employee of: Bristol-Myers Squibb, J. Zhu Employee of: Bristol-Myers Squibb, D. E. Furst Grant/research support from: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, Consultant for: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Cytori, Janssen, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, Speakers bureau: (CME only) AbbVie, Actelion, UCB, V. P. ...

Get information, facts, and pictures about Bristol-Myers Squibb Company at Encyclopedia.com. Make research projects and school reports about Bristol-Myers Squibb Company easy with credible articles from our FREE, online encyclopedia and dictionary.

PRIMARY OBJECTIVES:. I. To determine if treatment with combination paclitaxel and carboplatin (TC) chemotherapy does not result in an inferior death rate when compared to ifosfamide, mesna, and paclitaxel chemotherapy.. SECONDARY OBJECTIVES:. I. To determine if treatment with combination paclitaxel and carboplatin (TC) chemotherapy does not result in an inferior progression-free survival when compared to ifosfamide, mesna, and paclitaxel chemotherapy.. II. To determine if acute toxicity, specifically physician-assessed neurotoxicity and infection, associated with combination paclitaxel and carboplatin chemotherapy is reduced compared to that of ifosfamide, mesna, and paclitaxel chemotherapy.. III. To determine if treatment with combination paclitaxel and carboplatin chemotherapy is associated with superior patient-reported quality of life and neurotoxicity scores compared to that of ifosfamide, mesna, and paclitaxel chemotherapy.. TERTIARY OBJECTIVES:. I. To bank formalin-fixed, ...

TY - JOUR. T1 - Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint. AU - Sudo, Tamotsu. AU - Nitta, Masayuki. AU - Saya, Hideyuki. AU - Ueno, Naoto T.. PY - 2004/4/1. Y1 - 2004/4/1. N2 - Paclitaxel stabilizes microtubules, causing mitotic arrest and activating the spindle assembly checkpoint. We determined whether suppression of the checkpoint genes Mad2 and BubR1 affects paclitaxel resistance and whether overexpression of Mad2 protein in checkpoint-defective cells enhances paclitaxel sensitivity. Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity. In contrast, overexpression of Mad2 in cells with a checkpoint defect attributable to low Mad2 expression restored checkpoint function, resulting in enhanced paclitaxel sensitivity that correlated with enhanced cyclin-dependent kinase-1 activity. However, overexpression of ...

... NEW BRUNSWICK N.J. Nov. 30 /- Underscorin...The Bristol-Myers Squibb Pediatric Infectious Disease and ImmunologyC... At Bristol-Myers Squibb we believe that together we can prevail over...The new infectious disease and immunology center is the latest example...,Bristol-Myers,Squibb,,New,Jersey,Childrens,Hospital,Launch,Center,for,Immune,System,Disorders,&,Infectious,Diseases,Including,HIV/AIDS,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health

BACKGROUND: Less than 50% of ovarian cancers respond to paclitaxel. Effective strategies are needed to enhance paclitaxel sensitivity. METHODS: A library of silencing RNAs (siRNAs) was used to identify kinases that regulate paclitaxel sensitivity in human ovarian cancer SKOv3 cells. The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. All statistical tests were two-sided. RESULTS: Src family and Abl kinases were identified as modulators of paclitaxel sensitivity in SKOv3 cells. The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control

OREANDA-NEWS. Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the current indications for Opdivo to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy. Validation of the application confirms the submission is complete and begins the EMAs centralized review process.. The high frequency of metastatic urothelial carcinoma and its relapsing nature highlight the substantial need for new treatment approaches with high and durable responses, said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. We look forward to working with the EMA to potentially extend the use of Opdivo and bring the science of Immuno-Oncology to help patients in Europe fight this difficult-to-treat, advanced form of bladder cancer.. The application primarily included data from ...

Author Disclosures: C.N. Hess: None. S. James: Research Grant; Significant; AstraZeneca. Other Research Support; Modest; The Medicines Company, Correvio, Sanofi. Consultant/Advisory Board; Modest; Sanofi. D.M. Wojdyla: None. R.D. Lopes: Research Grant; Significant; Bristol-Myers Squibb, GlaxoSmithKline. Consultant/Advisory Board; Modest; Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer. D. Liaw: Employment; Significant; Bristol-Myers Squibb. E. Hagstrom: Honoraria; Significant; Sanofi. D.L. Bhatt: Research Grant; Significant; Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Roche, Sanofi Aventis, The Medicines Company. S. Husted: Research Grant; Significant; GlaxoSmithKline, Pfizer. Consultant/Advisory Board; Modest; Bayer, AstraZeneca, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim. S.G. Goodman: Research Grant; Significant; AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Pfizer, Sanofi. Honoraria; ...

mmuno-Oncology (I-O), and the research behind it, aspires to beat cancer at its own game. In February 2017, it was named advance of the year for a second year in a row by the American Society of Clinical Oncology (ASCO). The sheer amount of translational research underway with groundbreaking I-O approaches is very exciting, says Steven Averbuch, vice president, Translational Clinical Development & Pharmacodiagnostics at Bristol-Myers Squibb.. But despite the progress to date, less than 50 percent of patients respond to I-O, depending on the patient population and the specific types of cancers involved. A stat like that begs the question: Why do some people respond to immunotherapies while others dont?. Building on knowledge gleaned from nearly 20 years of researching immunotherapies, Bristol-Myers Squibb scientists are hunting for answers to that question at an accelerated pace with the help of cutting-edge technologies. They are investigating the biology of cancer and the immune system at ...

Using NOVO-DENTOCAINE LIQ 65MG/ML during pregnancy may raise the risk of children developing some disorder (commpon for some such kind of drugs), however it depends upon how NOVO-DENTOCAINE LIQ 65MG/ML ingredients pass through placenta and may have effect on baby - Strength of NOVO-DENTOCAINE LIQ 65MG/ML is major factor in determination of such side effects, The possible danger in pregnancy are under research. BRISTOL-MYERS SQUIBB, S.A Canada publish leaflet about NOVO-DENTOCAINE LIQ 65MG/ML every update to describe possible risks of using NOVO-DENTOCAINE LIQ 65MG/ML side effect in pregnancy and pregnant women. You may download BRISTOL-MYERS SQUIBB, S.A issued leaflet regarding side effects of NOVO-DENTOCAINE LIQ 65MG/ML - BENZOCAINE. Pregnancy Side Effects can be easily know by Atc code of NOVO-DENTOCAINE LIQ 65MG/ML ATC CODE.. ...

Faculty Disclosure. Dr Kane has been a consultant for Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, and Roche; has received honoraria from Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, and Roche; has been on the speakers/advisory boards for Bristol-Myers Squibb, Genentech, and Otsuka; and has been a stock shareholder in MedAvante.. Dr Correll has been a consultant for Bristol-Myers Squibb, Eli Lilly, Gerson Lehrman Group, Intra-Cellular Therapies, Lundbeck, MedAvante, Pfizer, ProPhase, Otsuka, Sunovion, and Vanda; has received grant/research support from Bristol-Myers Squibb, Janssen, Johnson & Johnson, Novo Nordisk A/S, and Otsuka; has received honoraria from Medscape; has been on the speaker/advisory boards of Alexza, Bristol-Myers Squibb, Eli Lilly, Genentech, Intra-Cellular Therapies, Lundbeck, Merck, ...

CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership for TARGET-NASH to a multi-year agreement. Bristol-Myers Squibb is committed to the discovery and development of

NEW YORK, May 30 - LabBook said Wednesday that it had signed an agreement to provide its XML browser to Bristol-Myers Squibb. Under the terms of the deal, LabBook will customize its Genomic XML Browser to allow Bristol-Myers Squibb researchers to access

In this study, evidence has been collected that supports the notion that paclitaxel may exert its toxicity via elevation of intracellular O2−, H2O2, and NO levels. This theory is confirmed by our data showing that (a) paclitaxel induced the production of O2−, H2O2 and NO; (b) paclitaxel induced oxidative DNA damage; (c) agents that decreased H2O2 and NO production suppressed paclitaxel-induced DNA damage, G2-M arrest, apoptosis, and cell growth inhibition; (d) inhibition of SOD or glutamylcysteine synthase increased paclitaxel-induced apoptosis; (e) cell lines with higher total antioxidant capacity were more resistant to paclitaxel cytotoxicity; and (f) agents that decreased clonogenic survival in paclitaxel-treated cells also decreased cellular total antioxidant capacity. Thus, paclitaxel chemoresistance correlates very well to intracellular antioxidant capacity.. Kong et al. ( 27) speculated that many chemotherapeutic agents exert their toxic effects on cancer cells by producing free ...

Disclosure of Interest R. Alten Grant/research support from: BMS, Merck Pharma GmbH, Wyeth Pharmaceuticals, Pfizer, Consultant for: Abbott Laboratories, Horizon Pharma, Merck Pharma GmbH, Nitec Pharma GmbH, Novartis Pharmaceuticals Corporation, Roche, Speakers bureau: Abbott Laboratories, BMS, Horizon Pharma, Merck Pharma GmbH, Novartis Pharmaceuticals Corporation, Roche, M. Hochberg Grant/research support from: NIH, Consultant for: Abbott Laboratories, Amgen Inc., BMS, Eli Lilly and Company, EMD Serono Inc., Genentech/Roche, Merck & Co., Inc., Novartis Pharma AG, Pfizer Inc, Speakers bureau: Bioberica SA, IBSA, Rottapharm/Madaus, R. Cohen Consultant for: Bristol-Myers Squibb, M. Weinblatt Grant/research support from: Bristol-Myers Squibb, Consultant for: Bristol-Myers Squibb, Abbott, J. Kaine Grant/research support from: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, UCB, E. Keystone Grant/research support from: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP;, ...

TY - JOUR. T1 - A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma. T2 - A Gynecologic Oncology Group Study. AU - Mannel, Robert S.. AU - Brady, Mark F.. AU - Kohn, Elise C.. AU - Hanjani, Parviz. AU - Hiura, Masamichi. AU - Lee, Roger. AU - DeGeest, Koen. AU - Cohn, David E.. AU - Monk, Bradley J.. AU - Michael, Helen. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment ...

Bristol-Myers Squibb Company (NYSE:BMY) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a collaborative clinical trial to evaluate the combination of Bristol-Myers Squibbs immunotherapy Opdivo (nivolumab) and Daiichi Sankyos investigational antibody drug conjugate DS-8201 in HER2-expressing metastatic breast and urothelial (bladder) cancers. We are excited to evaluate if the combination of these two mechanisms of action - the ability of an anti-PD-1 to harness the immune system and the potential of DS-8201 to deliver chemotherapy directly to target cancer cells - may be able to improve the outcomes of patients with HER2-expressing advanced breast and bladder cancer, said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. Pursuing combination studies like this is at the core of the Daiichi Sankyo Cancer Enterprise strategy, as we are looking to maximize the potential of our proprietary antibody ...

FDA Approves Sanofi-Aventis and Bristol-Myers Squibb New 300mg Loading Dose Tablet for PLAVIX BRIDGEWATER and PRINCETON, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Sanofi-aventis and Bristol-Myers

April 5, 2013. -Two Phase 2 studies to evaluate once-daily combination of Vertexs investigational nucleotide analogue VX-135 and BMS investigational NS5A replication complex inhibitor daclatasvir-. -Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013-. -Study in people with genotypes 1, 2 and 3 hepatitis C, including people with cirrhosis, planned for second half of 2013-. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company (NYSE: BMY) to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertexs nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Bristol-Myers Squibbs NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C. As part of the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in ...

TY - JOUR. T1 - Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer. T2 - a phase 3, open-label, randomised controlled trial. AU - Katsumata, Noriyuki. AU - Yasuda, Makoto. AU - Takahashi, Fumiaki. AU - Isonishi, Seiji. AU - Jobo, Toshiko. AU - Aoki, Daisuke. AU - Tsuda, Hiroshi. AU - Sugiyama, Toru. AU - Kodama, Shoji. AU - Kimura, Eizo. AU - Ochiai, Kazunori. AU - Noda, Kiichiro. N1 - Funding Information: SI and DA have received honoraria from Bristol-Myers Squibb. DA and HT have received grant support from Bristol-Myers Squibb. All other authors declare that they have no conflicts of interest. Funding Information: This study was funded by an unrestricted grant from Bristol-Myers Squibb. We thank the women who participated in this trial and Akihiro Yanagisawa, Kei Matsubara for assisting protocol design and review, Keiichi Fujiwara for internal auditing, and Robert F Ozols for protocol design and manuscript review. PY - 2009. Y1 - ...

Health,PRINCETON NJ -- Bristol-Myers Squibb has awarded a five-year $500000...Jeffrey S. Flier M.D. whose research in diabetes and obesity has ...Simeon Taylor M.D. Ph.D. vice president of Cardiovascular and Me... Dr. Taylor praised the discoveries and insights provided by Dr. Fl...,Unrestricted,metabolic,research,grant,awarded,to,Beth,Israel,Deaconess,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news

LOS ANGELES--Interim analysis of a major German-Austrian trial comparing cisplatin (Platinol)/paclitaxel (Taxol) with carboplatin (Paraplatin)/paclitaxel as first-line treatment in ovarian cancer found significantly less toxicity with carboplatin/paclitaxel, with no apparent loss of efficacy. 1

Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients

Grant Support: By the National Heart, Lung, and Blood Institute (contract N01-HC-35130). The ALLHAT investigators received study medications from Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support from Pfizer.. Potential Financial Conflicts of Interest:Consultancies: J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Merck & Co., Novartis Pharma AG, Pfizer, Phoenix Pharmaceuticals, Searle & Co., SmithKline Beecham, Solvay/Unimed); Honoraria: B.R. Davis (Pfizer), J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Merck & Co., Novartis Pharma AG, Pfizer, Phoenix Pharmaceuticals, Searle & Co., SmithKline Beecham, Solvay/Unimed), P. Whelton (Pfizer); Grants received: J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Eli Lilly & Co., Merck & Co., Novartis Pharma AG, Pfizer, Searle & Co., SmithKline Beecham, Solvay/Unimed); J.A. Cutler (Pfizer, AstraZeneca, Bristol-Myers ...

We believe that combination therapy may provide an important opportunity to address the needs of every patient with first-line lung cancer.. Previous studies with Opdivo have shown benefit and supported the approval of Opdivo for indications in several types of cancer, including previously treated metastatic non-small cell lung cancer. Patients who are being treated with Opdivo should continue their therapy as prescribed and consult with their healthcare provider in all aspects of care.. Everyone at Bristol-Myers Squibb is relentless in our pursuit to defeat cancer and bring transformational medicines to patients who are waiting.. U.S. FDA APPROVED INDICATIONS FOR OPDIVO®. OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.. OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is approved ...

AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin) PRINCETON, N.J. & WILMINGTON, Del., Jun 19, 2013...

TY - JOUR. T1 - Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. AU - Nguyen, Dao M.. AU - Chen, G. Aaron. AU - Reddy, Rishindra. AU - Tsai, Wilson. AU - Schrump, William D.. AU - Cole, George. AU - Schrump, David S.. AU - Jones, David A.. AU - Mentzer, Steven J.. AU - Harpole, David H.. PY - 2004/2. Y1 - 2004/2. N2 - Background: Constitutive activation of the phosphoinositide 3-kinase/protein kinase B survival signal transduction pathway influences the intrinsic chemoresistance of cancer cells. This study evaluates the effect of LY294002, a pharmacologic inhibitor of phosphoinositide 3-kinase, on the sensitivity of lung and esophageal cancer cells to paclitaxel (Taxol) in vitro. Materials and Methods: Cell viability and apoptosis of cancer cells treated with paclitaxel + LY294002 combinations were quantitated by methyl-thiazol-diphenyl-tetrazolium and ...

Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors

Were midway through the week and things have already been moving pretty fast. Action across the biotechnology sector is dictated by a variety of inputs but development stage pipeline updates are where the real action lies and - as we head into the bell on Wednesday - there are a couple of key pipeline related events that are going to set sentiment for the day. Heres a look at which companies are moving, whats moving each and whats next for the companies in question.. The two companies in focus for the session today are Bristol-Myers Squibb Company (NYSE:BMY) and Portola Pharmaceuticals Inc. (NASDAQ:PTLA).. First up, then, BMS.. After the closing bell rang on Tuesday, BMS announced top line data from a study called CheckMate-214. The trial was set up to investigate the potential use of Opdivo (nivolumab) in combination with Yervoy (ipilimumab), as compared to an already approved (and pretty well established) standard of care drug called sunitinib. The target indication in this instance was ...

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis. Additionally, our philanthropic programs have given new hope to some of the worlds most vulnerable communities and the preservation of our natural resources represents one of our key commitments. Our BioPharma strategy uniquely combines the best elements of a traditional pharmaceutical company with the entrepreneurial spirit and agility of a leading-edge biotech company - and our strategy is working. Since 2002, we have delivered 13 key new products to patients with serious diseases, four of these medicines are biologic products, and our pipeline continues to deliver. In 2011, we received approvals ...

FDA Approved Daklinza (Daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3. http://news.bms.com/press-release/fda-approves-daklinza-daclatasvir-treatment-patients-chronic-hepatitis-c-genotype-3, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Financial Help Info for Daklinza (daclatasvir) . http://www.daklinza.bmscustomerconnect.com/support, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Highlights of Prescribing Information - DAKLINZA. http://packageinserts.bms.com/pi/pi_daklinza.pdf, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Patient Support Connect. http://www.patientsupportconnect.bmscustomerconnect.com/, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. ...

Home » Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicines Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy ...

This Boston Biotech Just Got Scooped Up for $300M By Bristol-Myers Squibb - read this article along with other careers information, tips and advice on BioSpace

Product Details :: Buy Plavix by Bristol-Myers Squibb - Buy real authentic Steroids online, anabolic steroids, Injectable Steroids, Oral Steroids, anti estrogens, HGH & Peptides steroids by Geneza Pharmaceuticals, Biomex Labs, Asia Pharma, British Dispensary, Bayer, Lilly: - buy anabolic steroids, buy Injectable Steroids, buy Oral Steroids, buy anti estrogens, buy HGH & Pept - https://www.authenticpharm.com

Product Details :: Buy Bespar by Bristol-Myers Squibb - Buy real authentic Steroids online, anabolic steroids, Injectable Steroids, Oral Steroids, anti estrogens, HGH & Peptides steroids by Geneza Pharmaceuticals, Biomex Labs, Asia Pharma, Balkan Pharmaceuticals, Flonase, Casablanca Pharmaceuticals: - buy anabolic steroids, buy Injectable Steroids, buy Oral Steroids, buy anti estrogens, buy HGH & Pept - https://www.authenticpharm.com

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough

Source: S&P Capital IQ. TTM = trailing 12 months.. Unfortunately, that table doesnt tell us much about where Bristol-Myers Squibb has been, or where its going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it cant make up for this problem by cutting costs -- and most companies cant -- then both the business and its shares face a decidedly bleak outlook.. Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a companys profitability. Thats why I like to look at five fiscal years worth of margins, along with the results for the trailing 12 months, the last fiscal year, and last fiscal quarter. You cant always reach a hard ...

Multilind Suspension information about active ingredients, pharmaceutical forms and doses by Bristol-Myers Squibb, Multilind Suspension indications, usages and related health products lists

Explore comprehensive information about Bristol-Myers Squibb products including dosage and safety information. Learn more about our medicines today.

Stomahesive Powder information about active ingredients, pharmaceutical forms and doses by Bristol-Myers Squibb, Stomahesive Powder indications, usages and related health products lists

American pharmaceutical giant Bristol-Myers Squibb is set to buy US biotech company Inhibitex in a $2.5bn (£1.6bn) deal, bolstering its portfolio of drugs targeting the burgeoning hepatitis C market.

Former Bristol-Myers Squibb executive Robert Ramnarine of East Brunswick, N.J., pleaded guilty Monday in federal court in Trenton to charges that he got rich by using advance knowledge of the companys pending acquisition on Amylin in 2012. - David Sell, Philadelphia Inquirer

PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--April 27, 2006--Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of a product that combines the anti-HIV medications Sustiva(R) (efavirenz), manufactured by Bristol-Myers Squibb, and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), manufactured by Gilead Sciences, in a once-daily single tablet regimen. Truvada itself is a fixed-dose product that contains two of Gileads anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) (emtricitabine), in a single once-daily tablet. If approved by the FDA, the new single tablet regimen would be the first and only product that contains a complete Highly Active Antiretroviral Therapy (HAART) regimen in a single once-daily tablet, intended for the treatment of HIV-1 infection in adults as a complete regimen or in ...

Using DERMOPLAST AEROSOL SPRAY during pregnancy may raise the risk of children developing some disorder (commpon for some such kind of drugs), however it depends upon how DERMOPLAST AEROSOL SPRAY ingredients pass through placenta and may have effect on baby - Strength of DERMOPLAST AEROSOL SPRAY is major factor in determination of such side effects, The possible danger in pregnancy are under research. BRISTOL-MYERS SQUIBB, S.A Canada publish leaflet about DERMOPLAST AEROSOL SPRAY every update to describe possible risks of using DERMOPLAST AEROSOL SPRAY side effect in pregnancy and pregnant women. You may download BRISTOL-MYERS SQUIBB, S.A issued leaflet regarding side effects of DERMOPLAST AEROSOL SPRAY - BENZOCAINE. Pregnancy Side Effects can be easily know by Atc code of DERMOPLAST AEROSOL SPRAY ATC CODE.. ...

OBJECTIVES: To evaluate the efficacy of combination of navitoclax, carboplatin and paclitaxel in ovarian cancer.. METHODS: 8 ovarian cancer cell lines were treated with either doublet or triplet combinations of navitoclax, carboplatin and paclitaxel. Interactions were assessed by determining a combination index or measuring caspase activity. The effect of the combinations was also evaluated by measuring the inhibition of cells grown as spheroids.. RESULTS: Navitoclax exhibited modest (IC(50)=3-8 μM) single agent potency. Antagonism between carboplatin and paclitaxel was evident in Ovcar-4, Ovcar-8 and Skov-3 cells. Drug combinations including navitoclax with carboplatin and/or paclitaxel showed significantly less antagonism, or even synergy, in several cell lines than carboplatin/paclitaxel alone. Navitoclax enhanced the activation of caspase 3/7 induced by carboplatin and/or paclitaxel in Igrov-1 cells. Combinations of navitoclax, carboplatin and paclitaxel showed more than additive activity ...

Ampullary carcinoma is a rare tumor and evidence on the treatment of recurrent metastatic disease is scarce. We report the case of a 60-year-old patient with an R0-resected node-positive adenocarcinoma of the papilla of Vater of an initially diagnosed intestinal subtype who developed pulmonary metastases 2 months after adjuvant gemcitabine chemotherapy and, subsequently, liver metastases. Palliative combination chemotherapy with standard regimens for intestinal-type adenocarcinoma (FOLFOX and FOLFIRI) failed. However, subsequent combination chemotherapy with nanoparticle albumin-bound paclitaxel and gemcitabine, a regimen with proven efficacy in metastatic adenocarcinoma of the pancreas, resulted in a durable, very good partial remission. Treatment was manageable and well tolerated. Primary tumor and metastatic tissue were reassessed by immunohistochemistry and had to be reclassified to a mixed phenotype containing predominant elements of the pancreatobiliary subtype. Our case suggests that combination

Looking for online definition of Paclitaxel/Carboplatin or what Paclitaxel/Carboplatin stands for? Paclitaxel/Carboplatin is listed in the Worlds largest and most authoritative dictionary database of abbreviations and acronyms

Bristol-Myers Squibb Company (NYSE: BMY) and Emory University announced the formation of a strategic partnership to conduct clinical trials involving Bristol-Myers

TY - JOUR. T1 - A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. AU - Chen, Y. M.. AU - Perng, R. P.. AU - Shih, J. F.. AU - Lee, Y. C.. AU - Lee, C. S.. AU - Tsai, C. M.. AU - Whang-Peng, J.. PY - 2004/1/26. Y1 - 2004/1/26. N2 - Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus cisplatin (VC) in chemonaïve non-small-cell lung cancer (NSCLC) patients. From October 2000 to May 2002, 140 patients were enrolled. The treatment dose was P 66 mg m -2 intravenous infusion (i.v.) on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, or V 23 mg m-2 i.v. on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, every 4 weeks. In all, 281 cycles of PC and 307 cycles of VC were given to ...

This page contains abstract Effects of Gamma-linolenic Acid and Oleic Acid on Paclitaxel Cytotoxicity in Human Breast Cancer Cells http://www.chiro.org/nutrition/ABSTRACTS/Effects_of_Gamma_linolenic_Acid.shtml

TY - JOUR. T1 - A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. AU - Schiller, J. H.. AU - Storer, B.. AU - Tutsch, K.. AU - Arzoomanian, R.. AU - Alberti, D.. AU - Feierabend, C.. AU - Spriggs, D.. PY - 1994/11/3. Y1 - 1994/11/3. N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a novel antitubulin agent derived from the bark of the Pacific yew tree, may be one of the most active single agents in our chemotherapy armamentarium. Concern over acute hypersensitivity reactions has resulted in an administration schedule consisting of a 24-hour infusion. We conducted a phase I trial of a 3-hour infusion of paclitaxel to determine whether a 3-hour infusion could be administered with relative safety, and to identify the maximal tolerated dose with and without granulocyte colony-stimulating factor (G-CSF) support. Thirty-five patients with advanced, untreatable malignancies received a 3- hour infusion of paclitaxel once ...

On September 27, 2012, Justice Barnes of the Federal Court granted Bristol-Myers Squibb (BMS) an Order prohibiting the Minister of Health from issuing a notice of compliance (NOC) to Mylan Pharmaceuticals ULC for a generic efavirenz product (BMSs SUSTIVA) until the expiry of Patent No. 2,101,572 ( 572), but not Patent No. 2,279,198 ( 198). Canada Intellectual Property Smart & Biggar/Fetherstonhaugh 15 Oct 2012

Global Influenza Medication Market estimate based on the production chain, examination of various market participants, the general revenue earned by each player, production capability of Global Influenza Medication market, Future Strategies, Innovation, Technological trends with SWOT Analysis. Global Influenza Medication Market represented xx billion in 2018 and is projected to reach at a CAGR of xx% from 2019 to 2025. This Report covers a valuable source of perceptive information for business strategists.. Competitive Analysis:. The key manufacturers of the Global Influenza Medication Market: Bristol-Myers Squibb , AstraZeneca , Eli Lilly , Roche , GSK , Novartis , Pfizer , Sanofi , Bayer , Celgene , Seqirus , ,. Global Influenza Medication Market Report offers overall idea about key players and comprehensively analyses of their market position in terms of ranking, core competencies along with detailing the competitive landscape for the market leaders and rolling demand for the product from the ...

Bristol-Myers Squibb was developing inosine monophosphate dehydrogenase (IMPDH) inhibitors for the prevention of solid organ transplant rejection and for the

The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance

TY - JOUR. T1 - Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. AU - Xiong, Xiaoxiong. AU - Sui, Meihua. AU - Fan, Weimin. AU - Kraft, Andrew S.. N1 - Funding Information: This work was supported in part by NIH grant and CA92280 (to W.F.).. PY - 2007/7. Y1 - 2007/7. N2 - The combination of carboplatin and paclitaxel is widely used to treat multiple solid tumors including ovarian, lung and breast cancer. Usually these drugs are given simultaneously with little regard to the importance of scheduling to obtain a maximal response. To investigate the importance of sequencing, the human breast Bcap37 and ovarian OV2008 cancer cell lines were exposed to carboplatin and paclitaxel in three different sequences: (1) pretreatment with paclitaxel followed by carboplatin, (2) pretreatment of carboplatin followed by paclitaxel and (3) simultaneous treatment with these two agents. The combination of carboplatin and paclitaxel resulted in antagonistic ...

Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting. Patients with histologically confirmed recurrent OC, at the time of or more than 6 months after platinum-based chemotherapy, were randomized to six cycles of CP (carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21) or CLD (carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28). A total of 189 eligible patients (CP 96, CLD 93), with a median age of 63 years, median Performance Status (PS) 0 and a median platinum free interval (PFI) of 16.5 months, entered the study. Discontinuation due to toxicity was higher in the CP patients (13.5% versus 3%, P = 0.016). The overall response rate was similar: CP 58% versus CLD 51%, P = 0.309 (Complete Response; CR 34% versus 23%) and there was no statistical difference in time-to

TY - JOUR. T1 - Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. AU - Miller, Kathy D.. AU - Sisk, Judy. AU - Ansari, Rafat. AU - Gize, Gary. AU - Nattam, Sreenivasa. AU - Pennington, Kenneth. AU - Monaco, Frank. AU - Sledge, George W.. PY - 2001/12/1. Y1 - 2001/12/1. N2 - A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing metastatic breast cancer. To date, 27 patients have received paclitaxel at 175 mg/m2 over 3 hours on day 1, plus gemcitabine at 1,200 mg/m2 on days 1 and 8, plus trastuzumab at a 4-mg/kg loading dose on day 1, followed by 2 mg/kg weekly. Treatment cycles were repeated every 21 days. Responding or stable patients who had received six cycles of combination therapy continued single-agent trastuzumab weekly until disease progression. Treatment was generally well tolerated with grade 4 toxicity ...

BUFFALO, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the companys New Drug Application (NDA) for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.. In the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequelae on the Oral Paclitaxel arm compared with the IV paclitaxel arm.. The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by blinded ...

Japans largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

View more ,Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alternatively, nCRT with cisplatin plus fluorouracil (CF) can be used. Definitive chemoradiotherapy (dCRT) with CP or CF can be used if surgery is not planned. In the absence of comparative trials, we aimed to evaluate outcomes of CP and CF in the settings of TMT and dCRT. Methods: A single-site, retrospective cohort study was conducted at the Princess Margaret Cancer Centre to identify all patients who received CRT for locoregional esophageal or GEJ cancer. Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method and multivariable Cox regression model. The inverse probability treatment weighting (IPTW) method was used for sensitivity analysis. Results: Between 2011 and 2015, 93 patients with esophageal ...

Studies suggest that ω-3 polyunsaturated fatty acids (PUPAs) are beneficial in inhibiting the growth of cancer cells and may enhance the cytotoxicity induced by certain chemotherapeutic agents. It is known that seal oil is rich in ω-3 PUPAs. The effect of seal oil and its role on the cytotoxicity and apoptosis induced by paclitaxel was, therefore, investigated in breast cancer cell lines, MCF-7 and MDA-MB-231. -- MCF-7 and MDA-MB-231 cells were respectively treated with seal oil, paclitaxel, and paclitaxel in combination with seal oil. Cytotoxicity was evaluated by MTT assay. Apoptosis was investigated by morphological changes and DNA strand break assay. Western blot assay was used to assess the expression of p53 and Bcl-2 proteins. The lipid peroxide products were measured by thiobarbituric acid reactive substances (TEARS) assay and the intracellular lipid composition was determined by gas chromatography (GC). -- MTT assay showed that seal oil induced cell death and enhanced paclitaxel ...

In September of 2011, Ambrx entered into a worldwide collaboration with Bristol-Myers Squibb to develop and commercialize product candidates surrounding the Fibroblast Growth Factor 21 (FGF-21) protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure. Derivatives of FGF-21 and Relaxin were developed using Ambrxs unique ReCODE™ platform technology to modify the native proteins with amino acid building blocks beyond the 20 naturally occurring amino acids. Bristol-Myers Squibb and Ambrx also entered into research collaborations for both programs, which focus on engineering enhanced versions of the two target proteins for therapeutic use. In May of 2013, Ambrx entered into a collaboration agreement with Bristol-Myers Squibb for the discovery and development of novel antibody drug conjugates using Ambrxs Protein Medicinal Chemistry™ technology. These drug candidates will be based on Ambrxs EuCODE™ technology.. Read Press ...

TY - JOUR. T1 - Dicer elicits paclitaxel chemosensitization and suppresses cancer stemness in breast cancer by repressing AXL. AU - Chang, Ting Yu. AU - Chen, Hsin An. AU - Chiu, Ching Feng. AU - Chang, Yi Wen. AU - Kuo, Tsang Chih. AU - Tseng, Po Chun. AU - Wang, Weu. AU - Hung, Mien Chie. AU - Su, Jen Liang. PY - 2016/7/1. Y1 - 2016/7/1. N2 - Paclitaxel is a standard-of-care chemotherapy for breast cancer, despite the increasing recognition of its poor effectiveness in the treatment of patients with advanced disease. Here, we report that adenovirus-type 5 E1A-mediated elevation of the miRNA-processing enzyme Dicer is sufficient to enhance paclitaxel sensitization and reduce cancer stem-like cell properties in this setting. Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494, thereby repressing AXL expression to increase paclitaxel sensitivity. We found that Dicer expression was regulated at the transcription level by E1A, through activation of an MAPK14/CEBPα ...

PALIFERMIN, Palifermin, Paclitaxel protein-bound, PACLITAXEL, Paclitaxel, p24, Online Electronic Medical Diagnosis and Drugs, Medications, Articles, Glossary

TY - JOUR. T1 - Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials. AU - Comella, Pasquale. AU - Gambardella, Antonio. AU - Frasci, Giuseppe. AU - Avallone, Antonio. AU - Costanzo, Raffaele. AU - Gridelli, Cesare. AU - Stupp, Roger. AU - Scagliotti, Giorgio V.. AU - Comella, P.. AU - Frasci, G.. AU - Avallone, A.. AU - Costanzo, R.. AU - Gambardella, A.. AU - Bianco, M.. AU - Bilancia, D.. AU - Buzzi, F.. AU - Bartolucci, R.. AU - Cioffi, R.. AU - Messina, V.. AU - Carnicelli, P.. AU - De Cataldis, G.. AU - Del Gaizo, F.. AU - Del Prete, S.. AU - Di Lullo, L.. AU - Farris, A.. AU - Putzu, C.. AU - Filippelli, G.. AU - Olivito, V.. AU - Dima, G.. AU - Guida, M.. AU - Iannelli, A.. AU - Condemi, G.. AU - Mancarella, S.. AU - Maiorino, L.. AU - Musicò, M.. AU - Massidda, B.. AU - Ionta, M. ...

Purpose: Low-dose metronomic chemotherapy treatments, especially when combined with dedicated antiangiogenic agents, can induce significant antitumor activity without serious toxicity in various preclinical models. It remains unclear, however, whether some cytotoxic drugs are better suited for metronomic regimens than others. Paclitaxel appears to be a strong candidate for metronomic chemotherapy given its ability to inhibit endothelial cell functions relevant to angiogenesis in vitro at extraordinarily low concentrations and broad-spectrum antitumor activity. Clinically relevant concentrations of the formulation vehicle cremophor EL in Taxol, however, were previously reported to nullify the antiangiogenic effect of paclitaxel, the result of which would hamper its usefulness in metronomic regimens. We hypothesized that ABI-007, a cremophor EL-free, albumin-bound, 130-nm form of paclitaxel, could potentially alleviate this problem.. Experimental Design: The antiangiogenic activity of ABI-007 ...

Paclitaxel appears to be a potential substrate of the multidrug resistance protein p-glycoprotein, thus preventing itself from entry into the brain and penetrating blood-brain barrier poorly. In this study, the main objective was to design paclitaxel formulation using PLGA-based nanoparticles with different additives and surface coatings to facilitate the paclitaxel transport through MDCK cell monolayer. PLGA-based nanoparticles of around 200 nm without and with additives and surface coatings were developed by direct dialysis. The transendothelial electrical resistance (TEER) variation of MDCK cell monolayer on the cell inserts imposed by paclitaxel-loaded nanoparticles with and without additives was investigated. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) (MTT) assay was used to quantify the cell viability of C6 glioma cells after administration of formulations on the topical side. Investigations showed that particles with additives were able to enhance cellular ...

Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast cancer. It is yet unclear whether addition of capecitabine to the combination of these drugs improves the treatment outcome. Patients with advanced breast cancer were randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin(A (R))) and paclitaxel (Taxol(A (R))) alone (ET) or in combination with capecitabine (Xeloda(A (R)), TEX). Starting doses for ET were epirubicin 75 mg/m(2) plus paclitaxel 175 mg/m(2), and for TEX epirubicin 75 mg/m(2), paclitaxel 155 mg/m(2), and capecitabine 825 mg/m(2) BID for 14 days. Subsequently, doses were tailored related to side effects. Primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), time to treatment failure (TTF), objective response (OR), safety and quality of life (QoL). 287 patients were randomized, 143 to ET and 144 to TEX. Median PFS was 10.8 months for patients treated with ET, and ...

BACKGROUND: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx trade mark ) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics of PLD in this combination. METHODS: A phase I study was performed with an initial dose of 50 mg/m(2) wPTX and 30 mg/m(2) PLD. The paclitaxel dose was escalated in increments of 10 mg/m(2) and PLD in increments of 5 mg/m(2) until the MTD was reached. The pharmacokinetics of PLD were studied at the highest achieved dose levels. RESULTS: Forty-four cancer patients were enrolled. The MTD was 30/90 and 35/80 mg/m(2) for PLD/wPTX. Dose-limiting toxicities included treatment delay for neutropenia grade 3, febrile neutropenia, palmar-plantar erythrodysesthesia and deep venous thrombosis. Toxicity below the MTD was mild: skin toxicity grade 1-2 developed at high cumulative doses and vascular thrombotic events occurred in two patients with predisposing factors. No ...

At a median follow-up of 2.1 years, 23 patients had died. Of 10 patients in the intervention group, 2 died of renal cell carcinoma; of 13 in the active surveillance group, none died of the disease.. The cancer-specific survival rate exceeded 99% in both arms. Five-year overall survival was 92% with primary intervention and 75% for active -surveillance.. Two Paclitaxel Regimens Compared. In the treatment of breast cancer, dose-dense paclitaxel is often assumed to be more toxic than weekly paclitaxel, but investigators from Edwards Comprehensive Cancer Center in Huntington, West Virginia, reported that the regimens have a comparable tolerability profile.2. Mohamed Alsharedi, MD, suggested that some clinicians favor weekly paclitaxel because they deem the toxicities to be more than with dose-dense paclitaxel, based on the profile observed with weekly paclitaxel in the SWOG S0221 trial.3 To make treatment duration equal, however, SWOG S0221 tested six cycles of dose-dense paclitaxel, not four, which ...

Patients and Methods Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m2 on days 1, 8, and 15 plus cisplatin 60 mg/m2 on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m2 plus carboplatin area under the curve 6.0 mg/mL/min on day 1 every 3 weeks for six cycles (TC group). The primary end point was progression-free survival. Secondary end points were overall survival, overall response rate, and adverse events ...

In a phase II trial reported in JAMA Oncology by Debra L. Richardson, MD, of Stephenson Cancer Center, Oklahoma University Health Science Center, and colleagues, the addition of pazopanib (Votrient) to paclitaxel did not improve progression-free survival among women with persistent or recurrent ovarian cancer. In the double-blind study from 26 U.S. study sites, 106 women with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who had received 1 to 3 prior regimens were randomized between December 2011 and April 2013. They were treated with paclitaxel at 80 mg/m2 on days 1, 8, and 15 every 28 days plus pazopanib at 800 mg daily (n = 54) or placebo (n = 52). The median age of patients was 61 years. Median follow-up at the time of analysis was 17.7 months. Median progression-free survival was 7.5 months in the combination group vs 6.2 months with paclitaxel alone (hazard ratio [HR] = 0.84, P = .20). Objective response was observed in 31.8% vs 22.7% of ...